Sirio Pharma Co Ltd
SZSE:300791
Sirio Pharma Co Ltd
SZSE:300791
Price:
20.6
CNY
0.59%
Market Closed
Market Cap:
¥6.3B
Balance Sheet
Balance Sheet Decomposition
Sirio Pharma Co Ltd
Sirio Pharma Co Ltd
Balance Sheet Decomposition is not available for
Sirio Pharma Co Ltd
Sirio Pharma Co Ltd
Balance Sheet
Sirio Pharma Co Ltd
Sirio Pharma Co Ltd
Currency: CNY
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
270
|
111
|
72
|
72
|
217
|
709
|
1 389
|
522
|
633
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
709
|
1 389
|
522
|
633
|
|
| Cash Equivalents |
270
|
111
|
72
|
72
|
217
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
433
|
474
|
531
|
188
|
221
|
141
|
|
| Total Receivables |
377
|
188
|
251
|
260
|
342
|
416
|
490
|
669
|
734
|
|
| Accounts Receivables |
122
|
160
|
208
|
187
|
261
|
342
|
460
|
613
|
675
|
|
| Other Receivables |
255
|
28
|
43
|
73
|
81
|
74
|
31
|
56
|
59
|
|
| Inventory |
157
|
193
|
228
|
204
|
267
|
240
|
233
|
481
|
482
|
|
| Other Current Assets |
17
|
17
|
18
|
347
|
25
|
19
|
132
|
41
|
34
|
|
| Total Current Assets |
820
|
509
|
569
|
1 317
|
1 324
|
1 915
|
2 433
|
1 933
|
2 023
|
|
| PP&E Net |
302
|
401
|
589
|
639
|
786
|
1 179
|
1 339
|
1 961
|
2 124
|
|
| PP&E Gross |
302
|
401
|
589
|
639
|
786
|
1 179
|
1 339
|
1 961
|
2 124
|
|
| Accumulated Depreciation |
277
|
326
|
363
|
415
|
474
|
522
|
639
|
847
|
1 014
|
|
| Intangible Assets |
172
|
176
|
171
|
180
|
176
|
208
|
217
|
578
|
558
|
|
| Goodwill |
161
|
171
|
172
|
172
|
176
|
159
|
163
|
421
|
417
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
152
|
338
|
0
|
94
|
52
|
|
| Other Long-Term Assets |
19
|
31
|
42
|
53
|
36
|
22
|
35
|
209
|
311
|
|
| Other Assets |
161
|
171
|
172
|
172
|
176
|
159
|
163
|
421
|
417
|
|
| Total Assets |
1 475
N/A
|
1 288
-13%
|
1 544
+20%
|
2 359
+53%
|
2 650
+12%
|
3 820
+44%
|
4 186
+10%
|
5 196
+24%
|
5 486
+6%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
93
|
119
|
145
|
143
|
200
|
196
|
259
|
392
|
392
|
|
| Accrued Liabilities |
33
|
33
|
37
|
32
|
69
|
47
|
61
|
197
|
194
|
|
| Short-Term Debt |
242
|
100
|
166
|
35
|
2
|
0
|
0
|
6
|
56
|
|
| Current Portion of Long-Term Debt |
18
|
51
|
107
|
32
|
33
|
5
|
7
|
64
|
68
|
|
| Other Current Liabilities |
407
|
110
|
67
|
59
|
84
|
85
|
142
|
92
|
115
|
|
| Total Current Liabilities |
792
|
412
|
522
|
301
|
387
|
332
|
470
|
751
|
825
|
|
| Long-Term Debt |
147
|
223
|
158
|
32
|
0
|
869
|
929
|
1 305
|
1 484
|
|
| Deferred Income Tax |
0
|
0
|
8
|
12
|
15
|
12
|
23
|
28
|
15
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
176
|
135
|
|
| Other Liabilities |
74
|
73
|
72
|
68
|
65
|
61
|
62
|
545
|
521
|
|
| Total Liabilities |
1 013
N/A
|
708
-30%
|
760
+7%
|
414
-45%
|
467
+13%
|
1 275
+173%
|
1 484
+16%
|
2 806
+89%
|
2 980
+6%
|
|
| Equity | ||||||||||
| Common Stock |
60
|
60
|
60
|
80
|
120
|
180
|
180
|
182
|
236
|
|
| Retained Earnings |
271
|
399
|
603
|
745
|
978
|
1 138
|
1 278
|
1 496
|
1 623
|
|
| Additional Paid In Capital |
132
|
114
|
114
|
1 113
|
1 081
|
1 045
|
1 048
|
548
|
501
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
45
|
54
|
|
| Other Equity |
1
|
7
|
7
|
7
|
4
|
182
|
195
|
210
|
201
|
|
| Total Equity |
462
N/A
|
580
+26%
|
784
+35%
|
1 945
+148%
|
2 183
+12%
|
2 545
+17%
|
2 702
+6%
|
2 390
-12%
|
2 506
+5%
|
|
| Total Liabilities & Equity |
1 475
N/A
|
1 288
-13%
|
1 544
+20%
|
2 359
+53%
|
2 650
+12%
|
3 820
+44%
|
4 186
+10%
|
5 196
+24%
|
5 486
+6%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
228
|
228
|
228
|
304
|
304
|
304
|
305
|
303
|
307
|
|
Switch to:
Switch to:
See Also
Discover More
